Neogen Chemicals Step-Down Subsidiary Approves ₹76.8 Crore Allotment To Morita For 9.09% Stake

Market snapshot: Neogen Chemicals' step-down subsidiary, Neogen Morita New Materials Limited, has approved a preferential allotment of equity shares to its Japanese joint-venture partner, Morita Investment Limited. The transaction, valued at ₹76.8 crore, will dilute the existing holding structure and introduce the partner as a direct equity stakeholder in the lithium-ion battery materials business.

Data Snapshot

• Preferential allotment of 7.2 lakh equity shares approved by NML board at ₹1,066.66 per share.
• Morita Investment Limited to acquire a 9.09% post-allotment equity stake in the step-down joint-venture entity.
• The issue price includes a premium of ₹1,056.66 per share over the face value of ₹10 per share.

What's Changed

• Before the allotment, Morita Investment held 0% direct equity in NML, which was a wholly-owned step-down subsidiary of Neogen Chemicals.
• Post-allotment, Morita Investment will become a non-promoter public shareholder with a 9.09% stake, diluting Neogen's indirect holding.

Key Takeaways

• Board of NML approved the issuance of 7.2 lakh equity shares to Morita Investment at ₹1,066.66 per share on September 26, 2026.
• The allotment is executed under the Indo-Japan Joint Venture Agreement signed on August 31, 2025, to produce, develop, and sell battery materials.
• The ₹76.8 crore capital injection will strengthen the financing and execution of the joint venture's lithium-ion battery material project.
• This capital infusion supports the localized production of LiPF6 electrolyte salts, a critical EV battery chemical.

SAHI Perspective

This preferential issue is a vital operational milestone that transitions the Indo-Japan partnership from a contractual joint venture to an equity-aligned corporate structure. Direct capital participation by Japan's Morita Chemical Industries' arm confirms their long-term technical and commercial commitment. The funding arrives as Neogen completes an aggressive investment cycle, reducing project execution uncertainty for the step-down entity.

Market Implications

The direct equity involvement of a globally recognized Japanese technology partner enhances Neogen's positioning in the lithium-ion supply chain. This alignment is highly favorable for securing product qualifications and provisional supply approvals from international battery cell manufacturers.

Trading Signals

Market Bias: Bullish

Morita's direct ₹76.8 crore equity infusion in NML validates the Indo-Japan JV's electrolyte salt rollout. This, combined with Neogen's recent ₹599.99 crore QIP fundraise, significantly enhances capital flexibility as the Dahej and Pakhajan battery material projects near commissioning.

Overweight: Specialty Chemicals, EV Battery Materials

Trigger Factors:

• Commissioning and trial runs of Dahej and Pakhajan electrolyte facilities
• Securing final commercial supply approvals from domestic and global gigafactories

Time Horizon: Medium-term (3-12 months)

Industry Context

India's EV battery materials space is seeing accelerated localized development to offset deep import dependencies. Establishing a robust domestic manufacturing capability for electrolyte salts like LiPF6 is highly aligned with the government's push for domestic advanced chemistry cell (ACC) processing.

Key Risks to Watch

• Execution delays in commissioning the Pakhajan and Dahej battery chemical projects.
• Fluctuations in global lithium prices, which directly influence peak revenue potential and operating margins.
• Slower-than-expected commercial approvals from major international battery manufacturers.

Recent Developments

In September 2026, Neogen Chemicals successfully completed its first-ever QIP, raising ₹599.99 crore at ₹2,255 per share, which was oversubscribed by 6.5 times. Separately, in August 2026, NML approved a Business Transfer Agreement to acquire NIL's electrolyte salt assets for a lumpsum of ₹245 crore on a going concern basis. In Q1 FY27, Neogen's consolidated revenue rose 34.04% year-on-year to ₹250.29 crore, while consolidated net profit surged 66.76% to ₹17.11 crore.

Closing Insight

Aligning equity ownership with technology expertise is a proven risk-reduction strategy in complex chemical processing. This equity infusion positions Neogen to successfully navigate the capital-intensive scaling phase of its battery materials business.

High Performance Trading with SAHI.